XML 48 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Related Parties
12 Months Ended
Dec. 31, 2019
Text block [abstract]  
Related Parties
8. Related Parties
a. Related Parties
Balances and transactions between the Company and its subsidiaries and between subsidiaries have been eliminated in consolidation and are not disclosed in this note. The balances and transactions between the Company and its subsidiaries with other related parties are disclosed below:
 
   
Loans
 
   
Assets
   
Liabilities
 
Química da Bahia Indústria e Comércio S.A.
   0    2,875 
Others
   490    1,050 
  
 
 
   
 
 
 
Total as of December 31, 2019
   490    3,925 
  
 
 
   
 
 
 
   
Loans
 
   
Assets
   
Liabilities
 
Química da Bahia Indústria e Comércio S.A.
   —      2,925 
Others
   490    1,146 
  
 
 
   
 
 
 
Total as of December 31, 2018
   490    4,071 
  
 
 
   
 
 
 
Loans agreements have indeterminate terms and do not contain interest clauses. 
 
   
Commercial transactions
 
   
Receivables
(1)
   
Payables
(1)
   
Sales and
services
   
Purchases
   
Expenses
 
Oxicap Indústria de Gases Ltda.
   0    1,545    1    18,565    0 
Refinaria de Petróleo Riograndense S.A.
   0    264,602    0    1,019,108    0 
ConectCar Soluções de Mobilidade Eletrônica S.A.
   739    113    7,385    121    0 
LA’7 Participações e Empreend. Imob. Ltda. (a)
   0    124    0    0    1,477 
Chevron Latin America Marketing LLC
   0    0    0    0    0 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total as of December 31, 2019
   739    266,384    7,386    1,037,794    1,477 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
   
Commercial transactions
 
   
Receivables
(1)
   
Payables
(1)
   
Sales and
services
   
Purchases
   
Expenses
 
Oxicap Indústria de Gases Ltda.
   —      567    6    9,032    —   
Refinaria de Petróleo Riograndense S.A.
   —      24,630    —      1,008,860    —   
ConectCar Soluções de Mobilidade Eletrônica S.A.
   1,042    136    3,844    186    —   
LA’7 Participações e Empreend. Imob. Ltda. (a)
   —      117    —      —      1,469 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total as of December 31, 2018
   1,042    25,450    3,850    1,018,078    1,469 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
   
Commercial transactions
 
   
Receivables
(1)
   
Payables
(1)
   
Sales and
services
   
Purchases
   
Expenses
 
Oxicap Indústria de Gases Ltda.
   —      1,489    6    18,108    —   
Refinaria de Petróleo Riograndense S.A.
   —      22,199    —      1,004,030    —   
ConectCar Soluções de Mobilidade Eletrônica S.A.
   1,067    31    7,239    859    —   
LA’7 Participações e Empreend. Imob. Ltda. (a)
   —      125    —      —      2,300 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total as of December 31, 2017
   1,067    23,844    7,245    1,022,997    2,300 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
(1)
Included in “domestic trade receivables”, “domestic trade payables” and “domestic trade payables—reverse factoring”, respectively.
(a)
Refers to rental contracts of 15 drugstores owned by LA’7 as of December 31, 2019 and 2018, a company of the former shareholders of Extrafarma that are current shareholders of Ultrapar.
Purchase and sale transactions relate substantially to the purchase of raw materials, feedstock, transportation, and storage services based on similar market prices and terms with customers and suppliers with comparable operational performance. The above operations related to ConectCar Soluções de Mobilidade Eletrônica S.A. (“ConectCar”) refer to services provided. In the opinion of the Company and its subsidiaries’ management, transactions with related parties are not subject to credit risk, which is why no an estimated loss or collateral is provided. Collateral provided by the Company in loans of subsidiaries and affiliates are mentioned in Note 16.i.
 
b. Key executives
The Company’s compensation strategy combines short and long-term elements, following the principles of alignment of interests and of maintaining a competitive compensation, and is aimed at retaining key officers and remunerating them adequately according to their attributed responsibilities and the value created to the Company and its shareholders.
Short-term compensation is comprised of: (a) fixed monthly compensation paid with the objective of rewarding the executive’s experience, responsibility, and his/her position’s complexity, and includes salary and benefits such as medical coverage,
check-up,
life insurance, and others; (b) variable compensation paid annually with the objective of aligning the executive’s and the Company’s objectives, which is linked to: (i) the business performance measured through its economic value creation and (ii) the fulfillment of individual annual goals that are based on the strategic plan and are focused on expansion and operational excellence projects, people development and market positioning, among others. Further details about the Deferred Stock Plan are contained in Note 8.c and about post-employment benefits in Note 20.b.
The expenses for compensation of its key executives (Company’s directors and executive officers) as shown below:
 
   
2019
   
2018
   
2017
 
Short-term compensation
   41,659    36,504    45,477 
Stock compensation
   9,881    1,407    1,399 
Post-employment benefits
   2,640    2,278    1,096 
Long-term compensation
   0    —      (6,459
Termination benefit
   0    905    8,794 
  
 
 
   
 
 
   
 
 
 
Total
   54,180    41,094    50,307 
  
 
 
   
 
 
   
 
 
 
 
c. Deferred Stock Plan
Since 2003, Ultrapar has adopted a stock plan in which the executive has the usufruct of shares held in treasury until the transfer of the full ownership of the shares to those eligible members of management after five to seven years from the initial concession of the rights subject to uninterrupted employment of the participant during the period. The volume of shares and the executives eligible are determined by the Board of Directors, and there is no mandatory annual grant. The total number of shares to be used in the plan is subject to the number of shares in treasury. Ultrapar’s Board of Directors does not have a stock plan. The fair value of the awards w
as
 determined on the grant date based on the market value of the shares on the B3, the Brazilian Securities, Commodities and Futures Exchange and the amounts are amortized between five to seven years from the grant date.
The table below summarizes shares granted to the Company and its subsidiaries’ management:
 
Grant date
  
Balance of
number of
shares
granted
   
Vesting period
   
Market price of
shares on the
grant date (in
R$ per share)
   
Total grant
costs,
including
taxes
   
Accumulated
recognized
grant costs
  
Accumulated
unrecognized
grant costs
 
March 13, 2017
   200,000    2022 to 2024    34.00    9,378    (4,513  4,865 
March 4, 2016
   380,000    2021 to 2023    32.72    17,147    (11,164  5,983 
December 10, 2014
   533,324    2019 to 2021    25.32    27,939    (23,967  3,972 
March 5, 2014
   111,200    2020 to 2021    26.08    5,999    (5,610  389 
November 7, 2012
   —      2019    21.45    16,139    (16,139  —   
  
 
 
       
 
 
   
 
 
  
 
 
 
   1,224,524        76,602    (61,393  15,209 
  
 
 
       
 
 
   
 
 
  
 
 
 
In 2019, the amortization in the amount of R$ 10,321 (R$ 3,922 in 2018 and R$ 11,752 in 2017) was recognized as a general and administrative expense.
The table below summarizes the changes of number of shares granted:
 
Balance on December 31, 2017   2,366,796 
Cancellation of granted shares due to termination of executive employment
   (433,332
Shares vested and transferred
   (233,336
  
 
 
 
Balance on December 31, 2018   1,700,128 
Shares vested and transferred
   (475,604
  
 
 
 
Balance on December 31, 2019
   1,224,524 
  
 
 
 
The information above were adjusted retrospectively as disclosure in Note 26.a.
In addition, on April 19, 2017, the Ordinary and Extraordinary General Shareholders’ Meeting (“OEGM”) of approved a new incentive plan based on shares (”Plan”), which establishes the general terms and conditions for the concession of common shares issued by the Company and held in treasury, that may or may not involve the granting of usufruct of part of these shares for later transfer of the ownership of the shares, in periods of three to six years, to directors or employees of the Company or its subsidiaries.
As a result of the Plan, common shares representing at most 1% of the Company’s share capital may be delivered to the participants, which corresponds, at the date of approval of this Plan, to 11,128,102 common shares.
The table below summarizes the restricted and performance stock programs:
 
Program
  
Grant date
  
Balance of
number of
shares
granted
   
Vesting

period
   
Market price
of shares on
the grant date
(in R$ per
share)
   
Total
grant
costs,
including
taxes
   
Accumulated
recognized
grant costs
   
Accumulated
unrecognized
grant costs
 
Restricted
  October 1, 2017   240,000    2023    38.19    12,642    (4,741   7,901 
Restricted and performance
  November 8, 2017   75,876    2020 to 2022    38.19    5,014    (2,850   2,164 
Restricted and performance
  April 4, 2018   184,076    2021 to 2023    34.35    12,066    (5,539   6,527 
Restricted
  September 19, 2018   160,000    2024    19.58    4,321    (900   3,421 
Restricted
  September 24, 2018   80,000    2024    18.40    2,030    (423   1,607 
Restricted and performance
  April 3, 2019   558,708    2022 to 2024    23.25    24,096    (4,729   19,367 
Restricted
  September 2, 2019   440,000    2025    16.42    10,074    (560   9,514 
    
 
 
       
 
 
   
 
 
   
 
 
 
     1,738,660        70,243    (19,742   50,501 
    
 
 
       
 
 
   
 
 
   
 
 
 
In 2019, a general and administrative expense in the amount of R$ 12,893 was recognized in relation to the Plan (R$ 6,001 in 2018 and R$ 784 in 2017).
 
Balance on December 31, 2017   332,540 
Shares granted on April 9, 2018
   207,184 
Shares granted on September 19, 2018
   160,000 
Shares granted on September 24, 2018
   80,000 
Cancellation of granted shares due to termination of executive employment
   (39,772
  
 
 
 
Balance on December 31, 2018   739,952 
Shares granted on April, 3, 2019
   567,876 
Shares granted on September 2, 2019
   440,000 
Cancellation of granted shares due to termination of executive employment
   (9,168
  
 
 
 
Balance on December 31, 2019
   1,738,660 
  
 
 
 
The information above were adjusted retrospectively as disclosure in Note 26.a.